Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Breast Cancer AJCC v7: early-phase trial registry
1 of 12 indexed Stage III Breast Cancer AJCC v7 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 1 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Stage III Breast Cancer AJCC v7: 12 US clinical trials tracked, 1 recruiting.
Stage III Breast Cancer AJCC v7 is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition stage-iii-breast-cancer-ajcc-v7
OPEN 1 | RECR 8% | LATE 1 | EARLY 8 | RANK #1429 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Allergic Rhinitis (8% recruiting · 24 trials)
Stage III Breast Cancer AJCC v7 lists 1 open slots (8% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Breast Cancer AJCC v7 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Breast Cancer AJCC v7 is recruiting below its size-band peers.
1 of 12 indexed trials (8.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Breast Cancer AJCC v7 research.
National Cancer Institute (NCI) accounts for 5 of 12 trials (41.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage III Breast Cancer AJCC v7 enrolment sits around 110 participants.
Median target enrolment is 110 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Stage III Breast Cancer AJCC v7 research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
NCT03428802
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02954874
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
M.D. Anderson Cancer Center
NCT02276443
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
Academic and Community Cancer Research United
NCT03012100
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02498613
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
M.D. Anderson Cancer Center
NCT02754752
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes
M.D. Anderson Cancer Center
NCT02079662
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02311933
Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy
Mayo Clinic
NCT03281902
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
NCT02883062
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
NCT01463072
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Breast Cancer AJCC v7 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Breast Cancer AJCC v7 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Breast Cancer AJCC v7 page
12 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Stage III Breast Cancer AJCC v7 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage III Breast Cancer AJCC v7 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Breast Cancer AJCC v7 condition card totals 12 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.